

NEWS

FOR IMMEDIATE RELEASE

Contact: Evan Sherr
800-886-2966 Ext. 727

Cynosure Receives FDA Clearance for Pulse Dye Laser Treatment of Papillomatosis

Treatment May Eventually Provide Relief for Thousands of Patients World-Wide

Chelmsford, MA, (May 2, 2003)—Cynosure, Inc., a leading developer of laser solutions for aesthetic medicine today announced that it has received government clearance for the 585nm pulse dye laser (PDL) treatment of recurrent respiratory papillomatosis (RRP). The company is exhibiting at the Combined Otolaryngology Society Meetings (COSM), **Booth #123**, in Nashville, TN, May 2-5, 2003.

RRP, a benign neoplastic process, is an uncommon disease, caused by the human papilloma virus (HPV). It is potentially life-threatening if the airway becomes obstructed. The disease also causes difficulties in verbal communication and pain or discomfort. Treatment must balance decisions regarding airway safety, effects of multiple general anesthetics, and vocal dysfunction.

A pilot study by Drs. Ramon A. Franco, Jr., Willaim A. Farinelli, Steven M. Zeitels, and R. Rox Anderson (*Annals of Otolaryngology & Laryngology, June, 2000, Vol III, No. 6*) was conducted on 41 adult cases (23 patients, 78 vocal folds) without complication to evaluate the effectiveness of the Cynosure PhotoGenica V 585nm pulsed dye laser in the treatment of the disorder.

The study found that: "The use of the 585nm PDL for glottal papillomatosis was effective in enhancing the eradication of disease without clinically observed soft tissue complications associated with the CO₂ laser (thermal damage, tissue necrosis, superficial lamina propria scarring, anterior commissure web formation)."

The study went on to say: "It is readily apparent that PDL treatment offers relief of tumor burden and minimizes the attendant long-term consequences of vocal fold scarring that results from repeated surgical ablative procedures (CO₂ laser or cold instrument) required by dissection within the superficial lamina propria. Because epithelium is not fully removed, bilateral treatment of disease is possible.

"Anterior commissure disease (medial or internal surface), which is usually treated with staged operations, can be treated simultaneously, and thus the number of general anesthetic procedures, with their attendant morbidity and cost, is minimized."



Where art and science meet.

The pulse dye laser, originally developed by Horace Furumoto, Ph.D., founder and CEO of Cynosure Inc. and has been a workhorse in the treatment of a wide variety of skin conditions since its introduction in 1985 for the treatment of pediatric Port Wine Stain birthmarks.

The treatment of papillomatosis is the latest in a series of new applications for this technology. In 2001, Cynosure announced that it had received government clearance for the treatment of psoriasis using a unique patent-pending protocol, and its pulse dye technology. In 2002, the company received government clearance for treatment of wrinkles with the same technology. Its other uses include treatment of recalcitrant warts, facial rejuvenation, stretch marks and scars.

A clinical report summarizing the results of the papillomatosis treatment study is available from the company. Cynosure currently offers physicians a wide variety of vascular laser solutions designed to meet the needs of large, medium and small practices.

For more information, call 800-886-2966, or email via www.cynosurelaser.com.

About Cynosure

Cynosure develops, manufactures, and markets laser technology products at its Chelmsford, Massachusetts headquarters for worldwide distribution. The company's extensive product line includes the PhotoGenica® V family of vascular treatment/facial rejuvenation lasers, the Accolade™ laser for tattoo/pigmented lesion removal, the CO3™ laser for facial resurfacing, the Apogee™ family of hair removal lasers, and the Acclaim™ and Smartepil™ multi-application cosmetic lasers.

Today, thousands of pulse dye lasers are installed around the world and are used in the full range of vascular conditions, including facial and leg spider veins, port wine birthmarks, warts, rosacea, stretch marks, and scars.

In 2002, El. En., Italy's leading laser developer and manufacturer, acquired a majority position of Cynosure, Inc. The product mix of the two companies is highly complementary and will provide opportunities for growth through an increased mix of products and wider coverage of global markets. El. En. and Cynosure are working closely to optimize joint production processes, research and development efforts, and to exploit worldwide distribution channels.

Cynosure has offices in the United Kingdom, France, Germany, Singapore and Japan, and has forged a strategic partnership with Suzhou Cynosure Medical Devices in Suzhou, Peoples Republic of China. Cynosure's global reach extends to more than 60 nations and has given the company worldwide recognition in physician practices.

**10 Elizabeth Drive
Chelmsford, MA 01824
T 800.886.2966 - F 978-256-6556
www.cynosurelaser.com**